Zobrazeno 1 - 10
of 20
pro vyhledávání: ''
Autor:
Leomar Y. Ballester, Jay-Jiguang Zhu, Yuanqing Yan, Nitin Tandon, Meenakshi B. Bhattacharjee, Yoshua Esquenazi, Antonio Dono, Jennifer Vu, Gabriella Hines, Molly Anapolsky, Takeshi Takayasu
Publikováno v:
J Neurooncol
INTRODUCTION: Recently, the term “Diffuse glioma, BRAF V600E-mutant” has been recommended for IDH-wildtype gliomas with BRAF p.V600E mutation and without CDKN2A/B deletion. However, additional alterations in gliomas that coexist with BRAF-mutatio
Autor:
Kazunari Yoshida, Mizuto Sato, Yukina Morimoto, Yuki Kuranari, Masahiro Toda, Ryota Tamura, Yumiko Oishi, Kenzo Kosugi
Publikováno v:
Journal of neuro-oncology. 146(2)
Neurofibromatosis type 2 (NF2) patients uniformly develop multiple schwannomas. The tumor-microenvironment (TME) is associated with hypoxia and consists of immunosuppressive cells, including regulatory T cells (Tregs) and tumor-associated macrophages
Autor:
Antonello Vidiri, Veronica Villani, Isabella Sperduti, Laura Conti, Andrea Pace, Mariantonia Carosi, Chiara Mandoj, Anna Antenucci, Beatrice Casini, Alessandra Fabi, Tatiana Koudriavtseva
Publikováno v:
Journal of Neuro-Oncology. 138:527-535
Bevacizumab (BV), a neutralizing monoclonal antibody against the vascular endothelial growth factor ligand, is recognized as a potent anti-angiogenic agent with antitumor activity. The aim of this single-center, retrospective, longitudinal study was
Publikováno v:
Journal of neuro-oncology. 133(2)
During glioma resection, 5-aminolevulinic acid (5-ALA) and fluorescein sodium (Fl-Na) are used for photodynamic tumor visualization. The objective of this study was to evaluate the pathological findings of the boundary zone between the tumor and adja
Publikováno v:
Journal of Neuro-Oncology. 103:231-238
Glioblastoma multiforme (GBM) is a highly lethal brain tumor affecting children and adults, with the majority of affected individuals dying from their disease by 2 years following diagnosis. Other groups have reported the association of cytomegalovir
Autor:
Tomio Sasaki, Masahiro Mizoguchi, Toshio Uesaka, Akira Nakamizo, Tadahisa Shono, Toru Iwaki, Satoshi O. Suzuki, Hiroaki Niiro
Publikováno v:
Journal of Neuro-Oncology. 83:259-266
Vascular endothelial growth factor (VEGF) is considered to be a major regulator of angiogenesis in various brain tumors. In this study, we determined the expression levels of VEGF, and vascular endothelial growth factor receptor (VEGFR)-1 and -2 mRNA
Autor:
B Haylock, J.C. Broome, S Dodd, A Mat, Konstantina Karabatsou, N Moxam, M Aguirreburualde, Nikolai G. Rainov, P Pal, W Pinson-Ellis
Publikováno v:
Journal of Neuro-Oncology. 79:171-179
Primary central nervous system lymphomas (PCNSL) are rare tumours occurring in the brain. Their biology and the factors predicting survival are not well known. This study investigated expression of the antiapoptotic protein survivin and platelet-deri
Autor:
Ellen Gelpi, Karl Rössler, J. A. Hainfellner, Christine Marosi, Christine Haberler, Peter Birner, Herbert Budka
Publikováno v:
Journal of Neuro-Oncology. 76:105-109
Inhibition of tyrosine kinase (TK) receptors by synthetic small molecules has become a promising new therapy option in oncology. The TK inhibitor imatinib mesylate selectively targets PDGFR-alpha, -beta, c-kit, c-abl and arg and has proven successful
Publikováno v:
Journal of Neuro-Oncology. 66:139-146
In order to identify response predictors for a post-operative glioblastoma therapy consisting of tamoxifen, carboplatin and radiotherapy, expression of 12 antigens was evaluated in 36 newly diagnosed tumours and 13 recurrences. Results were correlate
Autor:
Shigetoshi Yano, Keishi Makino, Takuichiro Hide, Hideo Nakamura, Jun Ichi Kuratsu, Ken Ichi Iyama, Jun-ichiro Kuroda
Publikováno v:
Journal of neuro-oncology. 109(2)
Meningiomas are the most frequent intracranial tumors. Although most are benign WHO grade I tumors, grade II and III tumors are aggressive and survival is poor. Treatment options for grade II and III meningiomas are limited, and molecular targets are